Sistalgina

Quick links to important sections

Sistalgina

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sistalgina

Property Description
Active Ingredient Pramiverine (as hydrochloride)
Form Oral Tablet
Pharmacological Class Antispasmodic / Spasmolytic
General Purpose Relief of muscular spasms and cramping
Origin Synthetic small molecule compound

Sistalgina: Definition, Active Ingredient, and Drug Class

Sistalgina is a single-ingredient pharmaceutical preparation whose core identity is defined by its active chemical component, Pramiverine. This medication is clinically recognized as an effective antispasmodic agent, also correctly termed a spasmolytic, within the pharmacological domain. The active substance, often utilized as Pramiverine hydrochloride, is a synthetic small molecule compound, confirming its non-natural origin. Its structure and pharmacological action are noted in pharmaceutical literature as being effective in relaxing smooth muscle tissues. This confirms that the medication is specifically designed to reduce tension in involuntary muscles.

Pharmaceutical Form and General Purpose

Sistalgina is typically presented as an oral tablet, a standard solid pharmaceutical composition intended for internal delivery, distinguishing it as a single-ingredient product. The drug is known in certain markets, such as Chile, as a prescription-only medication for adult patient groups. The medication's general therapeutic purpose is to alleviate the acute discomfort and pain resulting from involuntary, excessive muscular contractions, known as spasms, in the body's internal tracts. Research into this class of medication confirms its primary role in addressing pain related to smooth muscle dysfunction, such as that experienced in sudden episodes of abdominal cramping. This supports the use of Sistalgina to help restore normal muscular tone and mitigate symptoms associated with spastic motility.

What side effects are possible with Sistalgina?

Possible side effects and safety information

The safety profile for Pramiverine (Sistalgina) is structured in official regulatory documents by the body systems affected and the observed frequency of reactions. The most common adverse effects listed are generally mild and related to the drug's activity as a smooth muscle antispasmodic.

System-Organ Classes and Frequency

The frequency classifications in regulatory summaries often describe the effects as generally mild or rare. Documented effects are grouped by system, including Gastrointestinal Disorders (dry mouth, constipation, diarrhea), Nervous System Disorders (dizziness), and Eye Disorders (blurred vision). Effects such as skin rashes and swelling are documented under Immune System/Skin Disorders, with significant swelling classified as a rare but potentially serious allergic reaction.

Classification Examples of Documented Effects
Common (Generally Mild) Dry mouth, Dizziness, Blurred vision
Other Constipation, Diarrhea, Skin rashes
Rare Allergic reactions, Hepatic Hypersensitivity

Safety Restrictions and Considerations

The official labeling notes that the most common side effects tend to diminish as the body adjusts to the medication over time. Crucially, the drug's use is restricted or requires caution in individuals with specific pre-existing conditions due to the risk of exacerbation, including Glaucoma, Myasthenia Gravis, and certain Severe Cardiovascular Disorders. Safety and effectiveness have generally not been established for pediatric use in official documents, and use during pregnancy is considered only when clearly needed.

Overdose and Emergency Response

Overdose and when to seek help for Sistalgina

Management of suspected Sistalgina (Pramiverine) overdose must strictly follow the universal emergency actions mandated by government regulatory authorities for medication poisoning.

Official regulatory documents do not detail specific clinical manifestations, signs, or symptoms for Pramiverine overdose. As a result, no formally described physiological findings, expected severe outcomes, or life-threatening complications are documented in the publicly accessible official labeling for this medication. This absence of specific clinical guidance necessitates a strict approach centered on immediate professional intervention.

The most critical regulatory statement is the requirement to seek immediate medical attention and contact emergency services for any suspected overexposure. This instruction serves as the mandated primary response to manage potential risk, as specific guidance on supportive management or monitoring is also not explicitly detailed.

Official labeling does not specify the existence of a particular antidote for Pramiverine overdose. Furthermore, no specific procedural steps, such as required gastric lavage or the administration of activated charcoal, are described in the accessible regulatory documents. No specific population constraints or increased risks for groups like the elderly or those with impaired function are documented in the official overdose sections. Urgent medical help is required immediately upon recognizing a suspected overdose, consistent with official regulatory guidelines for all medication-related emergencies.

Therapeutic Uses of Sistalgina

Sistalgina is an oral medication that provides supportive care for discomfort associated with smooth muscle spasms in several areas of the body. Its primary recognized uses relate to symptom relief in the gastrointestinal, urinary, and female reproductive tracts.

Sistalgina is utilized to help manage pain associated with spasms, which may arise from conditions affecting the stomach and intestines. This includes addressing episodes of colic-type pain and discomfort stemming from functional disorders.

Furthermore, the drug is administered to reduce discomfort linked to spasmodic issues in the biliary and urinary pathways. It also supports the management of conditions affecting female genital organs, such as dysmenorrhea (menstrual cramps).


Quick Facts

  • Supportive use: For discomfort related to smooth muscle spasm.
  • Primary applications: Gastrointestinal, urinary, and female reproductive tract spasms.
  • Key benefit: Symptom management for pain associated with colic or functional disorders.

Regulatory References

  1. Summary of Product Characteristics (SmPC) from the BPOM regulatory overview

Eligibility and Restrictions for Use

Official Eligibility and Contraindication Profile

The population authorized to use Sistalgina (Pramiverine hydrochloride) is strictly defined by regulatory authorities based on absolute contraindications and data limitations documented in the official prescribing information.

Eligibility Status Population or Condition
Contraindicated Known hypersensitivity to the drug; Glaucoma; Myasthenia gravis; Severe cardiovascular disorders; Prostatic hypertrophy or conditions causing urinary retention.
Not Recommended Pediatric Population (Children/Adolescents); Pregnant Women; Breastfeeding Women.

Age-Group Rules and Restrictions

The medicine is intended and generally authorized for adult patient groups. Use in the pediatric population is not recommended as safety and effectiveness have not been formally established. For older adults, use requires special caution due to increased susceptibility to effects that may influence heart rate and urinary function, as advised in regulatory warnings.

Conclusion of Eligibility

The official profile mandates that patients with the listed contraindications are explicitly prohibited from using the medicine. Eligibility is restricted to adults who do not possess these mandatory exclusionary conditions. For populations where data is insufficient, such as pregnancy and pediatrics, the regulatory status is officially designated as not recommended.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Sistalgina (Pramiverine) focuses on pharmacodynamic interactions and specific drug–substance constraints, as documented by government health authorities.

Interaction Scope

The primary interaction pattern is structured around the additive effects of co-administered substances.

Interaction Type Documented Constraint
Pharmacodynamic Interaction Co-administration with Anticholinergic Agents is documented to result in an additive effect, which increases the risk for anticholinergic-type adverse reactions.
Drug–Substance Restriction Co-administration with Alcohol carries a formal risk of potentiation of the effects of alcohol.

Official Interaction Profile

Official regulatory sources note that the simultaneous use of Sistalgina with other medicines that also possess anticholinergic properties can lead to increased potential for reactions such as dry mouth or blurred vision. These documented risks are based on the mechanism of pharmacodynamic reinforcement. No formal contraindications for co-administration are listed based solely on interaction risk in the official documentation. Furthermore, there are no explicitly documented metabolic interactions (e.g., specific CYP enzyme effects) or required time separation rules between doses. The information in the official labels is confined to these specific, documented pharmacodynamic and drug–substance interactions.

Mechanism of Action

Modulating Cholinergic Contraction Signals

The active ingredient, Pramiverine, acts as a competitive antagonist, primarily engaging the Muscarinic Acetylcholine Receptors ( M3 subtype) located on visceral smooth muscle cells. By blocking the binding site for the excitatory neurotransmitter, Acetylcholine (ACh), the drug modulates the pro-contractile input from the Parasympathetic Nervous System (PNS). This initial action modifies the signaling sequence that initiates the contraction of smooth muscle fibers.

Controlling Intracellular Calcium and Muscle Tension

Simultaneously, Pramiverine exerts a direct, non-receptor-mediated effect by inhibiting voltage-dependent Calcium Channels on the muscle cell membrane. This action limits the necessary influx of extracellular calcium ions ( Ca^2+). The resulting low concentration of free intracellular Ca^2+ prevents the activation of Myosin Light-Chain Kinase (MLCK), the enzyme crucial for the contraction cycle, leading directly to the physiological consequence of spasmolysis of the muscle tissue.

Dosage and Administration Information

Sistalgina is a single-ingredient formulation of Pramiverine, which is administered exclusively via the oral route. The medication is provided as a solid oral tablet form, designed for systemic absorption. The instructions for its use are documented in the prescribing information. This documentation defines the parameters for administration, ensuring standardized use across clinical practice.

The administration protocol specifies the numerical dose and frequency required for adult use, which is detailed in the prescribing information. The instructions also provide guidance on the use context, including any necessary relationship to food intake and conditions for swallowing the tablet.


Official Administration Guidelines

Feature Prescribing Details
Route of administration Oral route.
Dosing schedule Specific dose range and maximum recommended dose for adults are detailed in the prescribing information.
Timing in relation to meals Instructions for co-administration with food or intake timing are detailed in the clinical documentation.
Preparation requirements Any necessary handling or preparation procedures are specified in the documentation.
Age-group administration rules Dose adjustments or specific rules for defined populations (e.g., older adults) are provided when applicable.

Resulting Procedural Structure

The use involves taking the oral tablet as directed, according to the dose and schedule defined in the prescribing information. Adherence to the specific timing and procedural instructions is required for proper use.


Connection to the Overall Use Protocol

The overall use protocol for Sistalgina is structured by the instructions provided in the clinical documentation. These instructions define the oral administration of the tablet form, specify the numerical dosing and frequency, and outline the duration and special conditions necessary for use.

Recent Clinical Evidence

Sistalgina: Recent Clinical Evidence

Evidence for Use in Biliary Colic (Gallbladder/Bile Duct Spasms)

Research has explored the use of Pramiverine, the active component of Sistalgina, in individuals with acute pain episodes associated with spasms in the biliary tract. Studies examining this use include controlled clinical trials and observational research. These investigations used in research exploring how symptoms change over time, with researchers often relying on patient-reported outcomes describing discomfort to monitor outcomes related to physical discomfort.

Findings indicate patterns observed in the studies related to reported pain levels over short time frames, such as minutes or hours, following administration. Some older trials documented patient and physician global scores assessing overall symptomatic status. Evidence derived from settings with varying symptom burdens often stemmed from trials examining a combination formulation.

Long-term outcomes, maintenance effects, or impacts on disease progression are not well characterized by the existing evidence. Specific, large-scale randomized controlled trials (RCTs) investigating Pramiverine as a single agent for this condition are limited in modern published literature.


Evidence for Use in Renal and Urinary Tract Spasms

Pramiverine was evaluated in research exploring acute, severe pain linked to spasms in the urinary tract, such as those that may occur with kidney or ureter stones, in studies conducted during periods of increased symptom activity. Studies explored outcomes related to physical discomfort by measuring changes in pain intensity at set time intervals and monitoring outcomes related to physiological strain or stress.

Studies report how symptoms evolved in the observed populations in the acute setting, with findings documenting rapid changes in pain intensity shortly after administration. Data show patterns related to patient and physician assessments of the overall status in the emergency setting. Evidence derived from settings with varying symptom burdens often stemmed from trials examining a combination formulation of the drug.


What is Still Uncertain About Sistalgina Research

The evidence landscape, as described by scientific literature, is noted for certain limitations. A significant portion of the evidence is derived from trials where Pramiverine was observed in a combination product with an analgesic; therefore, subgroup findings are uncertain for the single ingredient. The evidence quality varies across studies and often relies on older research methodologies. The sample sizes were modest in some of the original studies, and comparative evidence is lacking against current, alternative treatments. The findings describe group patterns, not personal outcomes, and reflect the specific conditions under which they were conducted.

Frequently Asked Questions (FAQ)

Common questions about Sistalgina (FAQ)

Q: Can Sistalgina be used for period cramps that are very mild?

Official regulatory information describes Sistalgina as being indicated for the relief of pain resulting from muscular spasms. This use applies to spasms in the body's internal tracts, which can include various types of cramps. The official product information specifies the approved therapeutic indications for use.

Q: How long does it usually take for Sistalgina to start working?

Clinical evidence regarding the active ingredient indicates that changes in pain intensity are often observed rapidly after administration. These effects are typically noticed within a short time frame, usually described in regulatory documents as minutes or hours.

Q: How long do the effects of Sistalgina generally last?

The duration of the medication's effect is fundamentally governed by its pharmacological profile, specifically the elimination half-life. This is the measure used in regulatory documents to determine how quickly the active substance is cleared from the body.

Q: Is it normal if Sistalgina doesn't work right away for my pain?

Official regulatory documents set an expectation for a rapid onset of effect. The documentation details the proper time frame for assessing the efficacy of the medication.

Q: Does Sistalgina stop the cause of the cramps or just relieve the pain?

Sistalgina is classified as a spasmolytic agent, meaning its function is to directly relax involuntary smooth muscle contractions (spasms). By targeting the source of the spasm, the drug works to alleviate the resulting discomfort and acute pain.

Q: Are there specific types of pain that Sistalgina is not commonly used for?

Official regulatory documents specify that this medication is indicated for the relief of pain arising from muscular spasms in the internal organs. It is generally not indicated for use in treating other forms of pain that do not originate from these involuntary smooth muscle contractions.

Q: What happens if I forget a scheduled time I was meant to use Sistalgina?

Official administration guidelines published by regulatory authorities contain specific guidance for the event of a forgotten or missed dose. This guidance typically outlines the proper steps to address a missed dose and includes caution regarding taking a double dose.

Q: Can Sistalgina tablets be cut in half?

The official administration instructions detail all preparation requirements for the oral tablet form. This information specifies whether the tablet is scored and designed to be cut or divided for administration.

Q: Can Sistalgina cause long-term side effects if used often?

Clinical evidence for the single-agent formulation is noted in regulatory sources for having certain limitations regarding long-term use. The evidence base does not fully characterize long-term outcomes, maintenance effects, or safety when used over extended periods.

Q: Is fatigue or tiredness a common side effect of Sistalgina?

All officially documented side effects and their observed frequency, including Central Nervous System effects like dizziness, are detailed in the prescribing information. Feelings like fatigue or tiredness are not listed among the most commonly reported adverse effects.

Q: Does Sistalgina affect blood pressure or heart rate?

Due to the potential influence of the drug on heart rate, official labeling lists severe cardiovascular disorders as a contraindication. Furthermore, the use of the drug requires special caution for older adults due to increased susceptibility to effects on heart and urinary function.

Q: Are there specific signs of an allergic reaction to Sistalgina to look out for?

The official safety profile documents rare but potentially serious allergic reactions, noting that the occurrence of skin rashes and swelling, particularly significant swelling, is a specific concern detailed in the regulatory labeling.

Q: Can Sistalgina make you feel drowsy or affect driving ability?

Dizziness is listed as one of the commonly reported side effects of the medication. The official label includes a regulatory warning to use caution when performing activities that require full mental alertness, such as driving or operating machinery, due to the potential Central Nervous System effects like dizziness.

Q: Is it safe to use Sistalgina with common over-the-counter paracetamol?

The interaction profile defined by official sources focuses on known constraints, specifically co-administration with other anticholinergic agents and alcohol. The official regulatory information does not typically list the common non-interacting over-the-counter drugs, such as paracetamol.

Q: Can I drink coffee or caffeine while taking Sistalgina?

The official drug interaction profile is confined to specific, documented pharmacodynamic and drug-substance interactions. While alcohol is listed as a constraint, the profile does not note any specific interactions or constraints for the consumption of caffeine or coffee.

Q: Does Sistalgina interact with common cold or flu medications?

The official interaction profile warns about the additive effect when Sistalgina is combined with other medicines that also have anticholinergic properties. Some common cold or flu medications may contain these agents, leading to an increased risk of side effects like dry mouth or blurred vision.

Q: Can people over the age of 65 use Sistalgina?

Sistalgina is generally authorized for adult patient groups. However, the use of the medicine in older adults requires special caution. This is due to an increased susceptibility to effects that may influence heart rate and urinary function, as advised in regulatory warnings.

Q: Are there specific stomach or bowel conditions that make Sistalgina unsuitable?

The official contraindications profile lists conditions that can cause urinary retention, such as prostatic hypertrophy. While the medication is used to treat GI spasms, the full list of severe gastrointestinal or bowel conditions that would prohibit use is detailed in the official contraindications profile.

Q: Why is Sistalgina restricted for people with certain heart problems?

The official contraindication for severe cardiovascular disorders is linked to the drug's potential influence on heart rate and overall cardiovascular function. This restriction is mandated to mitigate the risk of exacerbation in individuals with severe pre-existing heart conditions.

Q: Can Sistalgina be used by patients with kidney problems?

The body eliminates the drug through the kidneys, as detailed in the official pharmacokinetic information. Official prescribing information addresses the use of the drug in individuals with compromised kidney or liver function, detailing the considerations related to administration and potential adjustments.

Q: Does Sistalgina contain common allergens like lactose or gluten?

The complete chemical composition of the tablet, including both active and inactive ingredients (excipients), is required to be documented in the official prescribing information. This list specifies the presence of any common allergens, such as lactose or gluten.

Q: Why is it generally important to follow the recommended time interval between doses?

The required time interval between doses is defined in the regulatory documents to ensure that the medication is effective and safe. This schedule prevents the accumulation of the drug in the body and helps avoid the risk of exceeding the maximum recommended daily dose.

Q: Does Sistalgina affect the results of any common lab tests?

Official regulatory labels are required to document if the medication is known to interfere with the results of any common laboratory or blood tests. This information is noted alongside warnings related to specific organs, such as those used for monitoring liver function.

Q: Is the packaging of Sistalgina typically child-resistant?

The official storage section includes the mandatory safety instruction to keep the medicine out of the sight and reach of children. This warning is a standard regulatory requirement to prevent accidental ingestion.

Q: What kind of pain relief can generally be expected from Sistalgina?

The medication's general therapeutic purpose, as defined by the official indication, is the alleviation of acute discomfort and pain. This relief is expected for symptoms that result from involuntary, excessive muscular contractions, commonly known as spasms, in the body's internal tracts.

Q: Do regulatory bodies advise special monitoring for long-term Sistalgina use?

While long-term outcomes are not well characterized, regulatory bodies require manufacturers to continually monitor the drug's safety after approval and report any newly identified long-term effects through a process called post-marketing surveillance.

Q: What are the most common reasons a doctor might advise against using Sistalgina?

The official contraindications listed on the regulatory label represent the primary reasons why use of the drug is prohibited. These mandatory exclusionary conditions include known hypersensitivity to the drug, glaucoma, and severe cardiovascular disorders.

Q: Does Sistalgina contain common allergens like lactose or gluten?

The official prescribing information lists all inactive ingredients (excipients) in the product. This list specifies the presence of common allergens like lactose or gluten, ensuring transparency regarding the full composition of the product.

Q: Is it okay to take a common painkiller for headaches at the same time as Sistalgina?

The official interaction profile does not list formal metabolic constraints with general, non-anticholinergic painkillers. All co-administration should be verified against the full regulatory document to ensure there are no specific concerns.

Q: Why do people sometimes report that Sistalgina makes them feel thirsty?

Dry mouth is classified as a commonly reported adverse effect of the medication. Since dry mouth is a known anticholinergic effect, this physiological change can lead to the feeling of thirst in patients.

Q: Can I use Sistalgina if I am taking hormonal birth control pills?

The official interaction profile is required to document any potential interactions with hormonal contraceptives (birth control pills) that may affect their efficacy, allowing for appropriate evaluation of concurrent use.

Q: Does Sistalgina stop working if you take it too often, according to studies?

The dosing and maximum frequency are clearly defined on the official label to ensure the medication maintains its efficacy. These instructions help prevent potential issues like a reduced therapeutic response or the occurrence of adverse effects from improper use.

Q: What are the ingredients used to coat the Sistalgina tablet?

The official prescribing information is required to list all ingredients, including the inactive materials used to coat the tablet or capsule. This detail ensures full transparency regarding the composition of the product.

Q: What should be done if Sistalgina is accidentally taken past its expiration date?

Official regulatory guidelines provide specific instructions for the proper disposal of unused or expired medicine, which typically involves local pharmaceutical waste programs rather than disposal in household trash or wastewater.

Q: What is the typical appearance of the Sistalgina tablet or capsule?

Official drug labels, such as the Summary of Product Characteristics (SmPC), include a physical description of the final product. This description details the typical color, shape, and any identifying markings on the tablet or capsule.

Q: Is Sistalgina a prescription-only medicine or over-the-counter?

The general dispensing status of the medication is based on national regulatory classification. Sistalgina is known in some markets, such as Chile, as a prescription-only medication for adults.

Q: How is Sistalgina described as being different from other common over-the-counter pain relievers?

The drug is classified as an antispasmodic/spasmolytic, and its mechanism targets smooth muscle contractions. This function differentiates it from common pain relievers, such as NSAIDs, which primarily work as general analgesics.

How should Sistalgina be stored and disposed of?

Sistalgina (Pramiverine hydrochloride) must be stored under specific environmental and container conditions to maintain its chemical stability and ensure product quality until the expiration date.

Official Storage and Disposal Requirements

Requirement Area Regulatory Constraint
Temperature Store generally below 30 C (86 F). Do not freeze.
Protection Must be protected from light and moisture.
Packaging Keep the medicine in its original container and, if applicable, keep the bottle tightly closed.
Child Safety Keep out of the sight and reach of children (mandatory safety instruction).
Disposal Dispose of unused medicine according to local or national pharmaceutical waste regulations; do not discard in household trash or wastewater.

These constraints ensure the product remains potent and safe as defined by regulatory standards for oral solid dosage forms.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sistalgina found in:

A-Z Index: